US Pat. No. 10,137,170

LIPIDATED INCRETIN RECEPTOR LIGAND HUMAN IMMUNOGLOBULIN FC-REGION FUSION POLYPEPTIDES

INDIANA UNIVERSITY RESEAR...

1. A fusion polypeptide comprisinga lipidated incretin receptor ligand polypeptide, and
a human immunoglobulin Fc-region, wherein said lipidated incretin receptor ligand polypeptide comprises the amino acid sequence of SEQ ID NO: 125 and the Fc-region comprises SEQ ID NO: 53 and said Fc-region is conjugated to either the carboxy terminus or amino terminus of the incretin receptor ligand polypeptide.
US Pat. No. 10,138,194

METHOD FOR PRODUCTION OF THYMOQUINONE

KEMIN INDUSTRIES, INC., ...

1. A method of producing thymoquinone, comprising the steps of:(a) cultivating plants of Monarda fistulosa either by planting seed or by transplanting cuttings;
(b) growing said plants of Monarda fistulosa until elevated levels of carvacrol and/or thymol are present in the plants;
(c) cutting said plants during their vegetative stage;
(d) allowing material of said cut plants to senesce in the presence of oxygen.
US Pat. No. 10,137,171

METHODS OF TREATMENT USING A PENTAPEPTIDE DERIVED FROM THE C-TERMINUS OF GLUCAGON-LIKE PEPTIDE 1 (GLP-1)

The General Hospital Corp...

wherein Xaa can be Gly, Gly-Arg, Gly-Arg-Gly, or absent,and a physiologically acceptable carrier, to a subject in need thereof.
US Pat. No. 10,137,172

ADMINISTRATION REGIME

1. An insulin titration method comprising:(a) obtaining a fasting blood or plasma sample, or non-invasive glucose measurement from an individual in need of treatment of type 2 diabetes;
(b) performing a single fasting blood or plasma glucose measurement on the sample obtained in (a);
(c) using the single fasting blood or plasma glucose measurement obtained in (b) to determine a LysB29(N?-hexadecandioyl-?-Glu) des(B30) human insulin (insulin degludec) dose to be administered; and
(d) administering said insulin to the individual at the dose determined in step (c);wherein subsequent doses of insulin are titrated by repeating step (a) and (b), the measurement being:?3.9 mmol/L (?70 mg/dL): the dose administered in step (d) is reduced by 4 U compared to the dose previously administered; or
4 to 5 mmol/L (71 to 90 mg/dL): the dose administered in step (d) is unaltered compared to the dose previously administered; or
?5.1 mmol/L (?91 mg/dL): the dose administered in step (d) is increased by 4 U compared to the dose previously administered;wherein step (d) is performed for an administration period of at least 3 days between two consecutive titrations; andwherein comparable improvements in HbA1c levels are seen relative to titration methods that are based on an average of at least three consecutive fasting blood glucose measurements per week.
US Pat. No. 10,138,196

PROCESS FOR PREPARING AN UNSATURATED CARBOXYLIC ACID SALT

BASF SE, Ludwigshafen (D...

1. A catalytic process for preparing an ?, ?-ethylenically unsaturated carboxylic acid salt, the process comprising:a) contacting an alkene and carbon dioxide with a carboxylation catalyst and an alkoxide, the alkoxide having a secondary or tertiary carbon atom directly bound to a [O?] group, to obtain a crude reaction product comprising the ?,?-ethylenically unsaturated carboxylic acid salt and an alcohol byproduct which is a conjugate acid of the alkoxide,
b) contacting at least part of the crude reaction product with a polar solvent such that a first liquid phase in which the ?,?-ethylenically unsaturated carboxylic acid salt is enriched, and a second liquid phase in which the carboxylation catalyst is enriched, are obtained, and
c) distilling an alcohol byproduct off from the first liquid phase.
US Pat. No. 10,137,173

ANTIVIRAL ACTIVITY OF GAS6 INHIBITOR

Aravive Biologics, Inc., ...

1. A method of inhibiting entry of an enveloped virus that expresses or incorporates phosphatidylserine in its outer membrane, into a cell, the method comprising:administering a soluble AXL variant polypeptide in a dose effective to inhibit the interaction between phosphatidylserine present at the outer membrane of the virus and of GAS6, wherein the virus is a filovirus, a lentivirus, a poxvirus, or a herpesvirus; and wherein said soluble AXL variant polypeptide lacks the AXL transmembrane domain and comprises amino acid modifications selected from the group consisting of:
(i) Gly32Ser, Asp87Gly, Val92Ala, and Gly127Arg; and
(ii) Gly32Ser, Ala72Val, Asp87Gly, Val92Ala, and Gly127Arg.
US Pat. No. 10,137,429

MOLECULAR ENCAPSULATION IN METAL-ORGANIC FRAMEWORK CRYSTALS

THE TRUSTEES OF BOSTON CO...

1. A host-guest complex comprising a metal-organic framework (MOF) as a host and a molecule as a guest, wherein the guest is encapsulated within the host; wherein the guest has a diameter larger than the aperture size of the host; wherein the MOF is (ZIF-8), and wherein the molecule is M-PPh3.
US Pat. No. 10,138,197

DIRECT CATALYTIC PARTIAL OXIDATION OF ALLYL ETHER

EXXONMOBIL RESEARCH AND E...

1. A process for forming allyl acrylate, comprising contacting allyl ether with a solvent, wherein the solvent is selected from acetonitrile, chloroform, dichloromethane, N,N-dimethylformamide, N,N-dimethyl acetamide, dimethyl sulfoxide, or dimethylcarbonate, and with an oxidant, wherein the oxidant is selected from oxygen, oxygen-containing gases, peroxides, and mixtures thereof in the presence of a mesoporous manganese oxide (MnOx) catalyst.
US Pat. No. 10,136,662

ORAL VIRUS VACCINE

University-Industry Found...

1. A polymer-coated porcine epidemic diarrhea virus particle for an oral vaccine, comprising:one or more porcine epidemic diarrhea virus particles for use as an oral vaccine;
a cationic polymer layer; and a pH-sensitive polymer layer coating said one or more porcine epidemic diarrhea virus particles,
wherein said cationic polymer layer and said pH-sensitive polymer layer are formed to coat said one or more porcine epidemic diarrhea virus particles, and any one of said cationic polymer layer and said pH-sensitive polymer layer is formed as an inner layer, and the other is formed as an outer layer, wherein:
said cationic polymer layer comprises one or more cationic polymers selected from the group consisting of polylysine, polyhistidine, and polyarginine;
said pH-sensitive polymer layer is ionized at pH 7 to 9; and
said pH-sensitive polymer layer comprises one or more pH-sensitive polymers selected from the group consisting of poly(methacrylic acid-co-ethyl acrylate), poly(methacrylic acid-co-methyl methacrylate), and poly(methyl acrylate-co-methyl methacrylate-co-methacrylic acid).
US Pat. No. 10,137,174

METHODS AND MATERIALS FOR TREATING CANCERS THAT EXPRESS REDUCED LEVELS OF WILD-TYPE P53 POLYPEPTIDES

Mayo Foundation for Medic...

1. A method for treating cancer in a mammal, wherein said method comprises:(a) identifying a mammal as having cancer cells that express a reduced level of wild-type p53 polypeptides, and
(b) administering, to said mammal, a USP10 polypeptide or composition that increases USP10 polypeptide expression or activity within said cancer cells and increases wild-type p53 polypeptide expression with said cancer cells, thereby reducing cancer cell proliferation within said mammal.
US Pat. No. 10,137,175

ANTIMICROBIAL AGENTS

LYSANDO AG, Triesenberg ...

1. A fusion protein having Gram-negative bacteria cell wall degrading activity comprising an endolysin and a heterologous peptide segment fused to the endolysin at the N- or C-terminus or at both termini, wherein the peptide segment exhibits an amino acid sequence selected from the group consisting of SEQ ID NO: 6 to 16 and 26 to 31.
US Pat. No. 10,138,199

HIGH ASPECT RATIO LAYERED DOUBLE HYDROXIDE MATERIALS AND METHODS FOR PREPARATION THEREOF

Saudi Arabian Oil Company...

1. A method for preparing adamantane-intercalated layered double-hydroxide (LDH) particles, the method comprising:adding to an aqueous solution a first precursor and a second precursor to form an initial mixture, where:
the first precursor is Al(OH)3 or Al2O3;
the second precursor is a hydroxide M(OH)2 or an oxide MO, where M is a metal of oxidation state +2; and
the initial mixture has a M/AI molar ratio from 1 to 5;
the initial mixture has a solid loading of less than 10 weight % solids, based on a total weight of the initial mixture;
adding to the initial mixture an amount of adamantane to form a reaction mixture having an Al/adamantane molar ratio from 0.5 to 2; and
heating the reaction mixture to produce the adamantane-intercalated LDH particles, where the adamantane-intercalated LDH particles have an aspect ratio greater than 100, the aspect ratio defined by a width of an adamantane-intercalated LDH particle divided by a thickness of the adamantane-intercalated LDH particle.
US Pat. No. 10,137,176

COMPOSITIONS AND METHODS FOR TREATING MPSI

The Trustee of the Univer...

1. A recombinant adeno-associated virus (rAAV) particle having an AAV capsid and having packaged therein a 5? inverted terminal repeat (ITR), a human alpha-L-iduronidase (hIDUA) gene under the control of regulatory sequences which control expression thereof, and an AAV 3? ITR, wherein said hIDUA gene has a sequence of SEQ ID NO: 1 or a sequence at least about 95% identical to SEQ ID NO: 1 which encodes a functional human alpha-L-iduronidase.
US Pat. No. 10,138,969

FRICTION MATERIAL

Nisshinbo Brake, Inc., T...

1. A friction material utilized for a disc brake pad, which is manufactured by forming a friction material composition, whereinsaid friction material composition contains 4-12 weight % of a binder relative to the total amount of the friction material composition, 3-8 weight % of an organic friction modifier relative to the total amount of the friction material composition, 7-35 weight % of a sheet shape titanate relative to the total amount of the friction material composition, and 0.3-5 weight % of an exfoliated graphite particle with an average particle diameter of 1-100 ?m, relative to a total amount of the friction material composition as a lubricant and a total amount of a copper component contained in the friction material composition is less than 5 weight % relative to the total amount of friction material composition.
US Pat. No. 10,136,666

DEEP EUTECTIC SOLVENTS AND FLAVOUR GENERATION

Nestec S.A., Vevey (CH)

1. A process for the preparation of a flavor composition comprising the steps:forming a deep eutectic solvent;
preparing a reaction mixture comprising the deep eutectic solvent and flavor precursors selected from the group consisting of amino acids and peptides; and heating the reaction mixture to form aroma compounds, wherein the deep eutectic solvent is a liquid comprising a combination of at least two compounds solid at 25° C. and comprises water and/or glycerol in an amount insufficient to dissolve all the compounds solid at 25° C. individually, or in an amount such that all the compounds solid at 25° C. are simultaneously saturated at 25° C., wherein the flavor precursors comprise the compounds solid at 25° C., and wherein the at least two compounds solid at 25° C. are selected from the group consisting of: amino acids; organic acids having 6 carbons or fewer; monosaccharides or disaccharides; sugar alcohols having 12 carbons or fewer; choline chloride; betaine; carnitine; edible salts of sodium, potassium, magnesium or calcium; ribonucleotides; and urea; with the proviso that the two compounds are not both edible salts of sodium, potassium, magnesium or calcium; or are not both ribonucleotides.
US Pat. No. 10,137,178

DENTAL GEL COMPOSITION OF PAPAIN FOR THE ATRAUMATIC TREATMENT OF CARIES AND METHOD OF PREPARING SAME

BRIX USA, LLC, Newark, D...

1. A dental composition of papain in the form of a gel for the atraumatic treatment of caries comprising papain with a final activity of at least 3,000 U/mg, wherein the papain is bio-encapsulated in a mixture comprising all of the following ingredients:pH=7 buffer,
a C3-6 polyol,
pectin,
C2-6 alkanolamine,
a nonionic emulsifier,
optionally a pharmaceutically acceptable coloring agent
a preservative, and
a solvent,
wherein the composition does not include chloramine.
US Pat. No. 10,138,459

BACTERIAL STRAIN RHODOCOCCUS AETHERIVORANS VKM AC-2610D PRODUCING NITRILE HYDRATASE, METHOD OF ITS CULTIVATION AND METHOD FOR PRODUCING ACRYLAMIDE

Kemira Oyj, Helsinki (FI...

1. A method of culturing a bacterial strain Rhodococcus aetherivorans VKM Ac-2610D, wherein cells of the strain are cultured using a nutrient medium comprising:an aqueous phosphate buffer comprising sodium and potassium ions;
a source of carbon;
a source of nitrogen;
optionally an enzyme inducer;
optionally a cobalt salt;
a magnesium salt;
a zinc salt;
a calcium salt; and
a Fe(II) salt.
US Pat. No. 10,139,743

TONERS FOR DEVELOPING ELECTROSTATIC IMAGES AND PRODUCTION METHOD THEREOF

Samsung Electronics Co., ...

1. A toner for developing electrostatic images, the toner comprising:a binder;
a colorant;
iron;
silicon; and
sulfur;
wherein an amount of the iron is greater than or equal to 1.0×103 ppm and less than or equal to 1.0×104 ppm;
an amount of the silicon is greater than or equal to 1.0×103 ppm and less than or equal to 5.0×104 ppm;
an amount of the sulfur is greater than or equal to 500 ppm and less than or equal to 3000 ppm;
an amount of the colorant is greater than or equal to 3.5 wt % and less than or equal to 7 wt % based on a total weight of the toner;
the colorant comprises a phosphor and a non-fluorescent colorant;
an amount of the phosphor is greater than or equal to 0.25 wt % and less than or equal to 4.55 wt % based on the total weight of the toner;
the phosphor comprises either one or both of a nitride and an oxynitride each comprising an alkaline-earth metal, silicon, and an activator element comprising any one or any combination of any two or more of europium (Eu), cerium (Ce), manganese (Mn), praseodymium (Pr), neodymium (Nd), samarium (Sm), terbium (Tb), dysprosium (Dy), holmium (Ho), erbium (Er), thulium (Tm), and ytterbium (Yb);
a volume average particle diameter of the phosphor is greater than or equal to 50 nm and less than or equal to 400 nm; and
an internal quantum efficiency of the phosphor at an excitation wavelength of 450 nm is greater than or equal to 60%.
US Pat. No. 10,136,667

THICKENING COMPOSITION AND METHOD FOR PRODUCING SAME

MATSUTANI CHEMICAL INDUST...

1. A thickening composition, consisting of:a thickening polysaccharide; and a metal salt-enclosing dextrin, wherein
the metal salt is selected from the group consisting of calcium lactate, calcium acetate, calcium gluconate, calcium pantothenate, calcium ascorbate, magnesium sulfate, trisodium citrate, and tripotassium citrate;
the thickening polysaccharide is selected from the group consisting of xanthan gum, carrageenan, guar gum, locust bean gum, tara gum, and glucomannan;
a mass ratio of the thickening polysaccharide to a total metal salt-enclosing dextrin is from 46:54 to 70:30; and
a ratio in parts by mass of the total metal salt is 3.5 to 12.8 parts by mass relative to 100 parts by mass of the thickening polysaccharide,
wherein the dextrin has a DE of 8 to 25.
US Pat. No. 10,138,460

DEVICES, SYSTEMS AND METHODS FOR THE PRODUCTION OF HUMANIZED GUT COMMENSAL MICROBIOTA

1. A method for ex vivo production of human gut microbiota, comprising:screening a first sample of gut microbiota obtained from a first human subject to detect or remove ova, parasites, or viruses;
immobilizing the screened gut microbiota on a growth template coated with human cells, tissue extracts, adhesive proteins, or commensal colonizing factors;
seeding a synthetic, ex vivo culture medium with the immobilized sample;
adding nutrients to the synthetic culture medium to produce both cultured aerobic and anaerobic gut microbiota;
maintaining the temperature and gas gradients of the culture medium so as to be similar to the human gut; and
harvesting the cultured gut microbiota.
US Pat. No. 10,139,744

ELECTROSTATIC LATENT IMAGE DEVELOPING TONER

KYOCERA Document Solution...

8. An electrostatic latent image developing toner comprising toner particles each including a toner core and a shell layer covering a surface of the toner core, whereinthe shell layer contains a hydrophilic thermosetting resin and a hydrophobic thermoplastic resin,
the hydrophilic thermosetting resin is a resin having at least one functional group selected from the group consisting of oxazoline groups, carbodiimide groups, and isocyanate groups,
the hydrophobic thermoplastic resin is exposed at surfaces of the toner particles, and
the hydrophilic thermosetting resin is a polymer of a monomer containing at least one compound selected from the group consisting of 2-isopropenyl-2-oxazoline, 2-(penta-4-ynyl)-2-oxazoline, 2-isocyanatoethyl acrylate, and 2-isocyanatoethyl methacrylate.
US Pat. No. 10,136,668

LOW PROTEIN INFANT FORMULA WITH INCREASED ESSENTIAL AMINO ACIDS

N.V. Nutricia, Zoetermee...

1. An infant formula composition comprising protein, digestible carbohydrates and fat, wherein the protein comprises amino acids leucine, isoleucine and valine in a weight ratio leucine:isoleucine:valine is between (1.1-1.5):(0.9-1.1):1.0, wherein the total protein content is between 1.3 and 1.9 protein/100 kcal.
US Pat. No. 10,137,180

METHODS FOR REGULATING PROTEIN FUNCTION IN CELLS IN VIVO USING SYNTHETIC SMALL MOLECULES

THE BOARD OF TRUSTEES OF ...

1. An in vivo method for increasing the stability of IL-2 or TNF-? in a mammal comprising:(a) introducing into one or more mammalian cells in vitro, a nucleic acid comprising a polynucleotide encoding a fusion protein, wherein the fusion protein comprises in an N-terminal to C-terminal direction:
i) a signal peptide, wherein the signal peptide facilitates secretion of the fusion protein,
(ii) a single-polypeptide chain, ligand-dependent, stability-affecting FKBP variant protein, comprising F36V and L106P amino acid substitutions fused to the signal peptide, and
(iii) IL-2 or TNF-? fused to the stability-affecting FKBP variant protein,
wherein said introducing generates one or more transformed mammalian cells expressing and secreting the fusion protein;
(b) implanting the one or more transformed cells from (a) into a mammal harboring a tumor, and
(c) administering a Shield1 ligand to the mammal from (b), wherein the Shield1 ligand binds to the stability-affecting FKBP variant protein and said binding increases stability of IL-2 or TNF-? by reducing degradation of the fusion protein, increases regulatory T-cell infiltration into tumor cells, and increases the survival rate of the mammal when compared to the same species of mammal constitutively expressing IL-2 or TNF-?.
US Pat. No. 10,137,436

HYDROGENATION CATALYST FOR HEAVY HYDROCARBON OIL AND HYDROGENATION METHOD FOR HEAVY HYDROCARBON OIL

COSMO OIL CO., LTD., Tok...

1. A hydrogenation catalyst for heavy hydrocarbon oil,wherein at least one of metals in Group 6 of the periodic table is supported on a zinc-containing alumina carrier containing 1% by mass to 15% by mass of zinc oxide particles having an average particle diameter of 2 ?m to 12 ?m based on the carrier,
the average pore diameter is 18 nm to 35 nm, and
the specific surface area is 70 m2/g to 150 m2/g.
US Pat. No. 10,138,204

METHOD FOR PRODUCING N-RETINOYLCYSTEIC ACID ALKYL ESTER

ARDENIA INVESTMENTS, LTD,...

1. A method for producing derivatives of N-retinoylaminoalkane sulfonic acid, the method comprising providingi) a first solution comprising an aminoalkane sulfonic acid selected from the group consisting of cysteic acid and alkyl ester thereof, cysteinesulfinic acid and alkyl ester thereof, homocysteic acid and alkyl ester thereof, homocysteinesulfinic acid and alkyl esters thereof, taurine and derivatives thereof, an alcohol selected from aliphatic alcohols comprising 1 to 4 carbon atoms and a first base selected from trialkylamines,
ii) a second solution comprising a retinoic acid, a chloroformate, an aprotic solvent and a second base,
adding first and second solutions in any order to a reaction vessel thereby forming a reaction mixture comprising at least a liquid phase being one phase, mixing said reaction mixture, wherein retinoic acid, aminoalkane sulfonic acid and chloroformate are all soluble and present in said liquid phase and the derivatives of N-retinoylaminoalkane sulfonic acid are formed in said liquid phase under conditions characterised as being substantially free from oxidizing compounds.
US Pat. No. 10,138,461

ANIMAL PROTEIN-FREE MEDIA FOR CULTIVATION OF CELLS

Baxalta Gmbh, Glattpark ...

1. An animal protein-free cell culture medium, comprising at least one polyamine and at least one protein hydrolysate derived from the group consisting of plants and yeast, wherein the polyamine is present in the culture medium in a concentration ranging from about 0.5 to about 30 mg/L.
US Pat. No. 10,136,669

METHOD FOR DECREASING VISCERAL FAT OR INCREASING ENERGY CONSUMPTION

AJINOMOTO CO., INC., Tok...

1. A method for decreasing visceral fat or increasing energy consumption, comprising administering to a subject in need thereof an effective amount of a composition comprising:i) n-3 fatty acid, and
ii) an ingredient selected from the group consisting of free lysine, dipeptides containing lysine and lysine salts, and combinations thereof;
wherein the ingredient is present in the composition in an amount of 0.1 g-10.0 g per 100 kcal of the composition, and
wherein the n-3 fatty acid is present in the composition in an amount of 0.17 g-5.00 g per 100 kcal of the composition.
US Pat. No. 10,137,181

ISOLATED DONOR MHC-DERIVED PEPTIDE AND USES THEREOF


US Pat. No. 10,137,437

METHOD FOR PRODUCING A CATALYST FOR THE PARTIAL OXIDATION/AMMOXIDATION OF OLEFINS

Clariant Corpoation, Lou...

1. A method for producing a catalyst which includes as the catalytically active component a compound having the general formula MoxBiyFezAaBbCcDdOv, where A stands for Ni and/or Co, B stands for one or more metals selected from Mg, Cr, Mn, Zn, Ce, and Ca and combinations thereof, C stands for W, and D stands for one or more alkali metals, where x stands for a number from 10 to 14, y stands for a number from 0.1 to 5, z stands for a number from 0.5 to 5, a stands for a number from 1 to 10, b stands for a number from 0.1 to 6, c stands for a number from ?0 to 2, d stands for a number from 0.02 to 2, and v is determined by the oxidation state of the elements, the method including the following steps:a) providing a solution in which all precursor compounds of the Mo, Bi, Fe, A, B, C and D components of the catalytically active component are essentially completely dissolved in a suitable solvent;
b) bringing the solution obtained in step a) into contact with a chemically inert, porous support having a specific surface of 1 to 500 m2/g; and
c) heat treatment of the material obtained in step b), in which the precursor compounds of the catalytically active component are converted to their oxides.
US Pat. No. 10,138,462

NATURAL KILLER CELL LINES AND METHODS OF USE

NANTKWEST, INC., San Die...

1. A method of treating a cancer in vivo in a mammal comprising the step of administering to the mammal a medium comprising an NK-92 cell line ATCC Deposit No. CRL-2407, wherein said cancer is recognized and lysed by said NK-92 cell line and wherein said cancer is a solid tumor.
US Pat. No. 10,137,182

CANCER VACCINES AND VACCINATION METHODS

Immunocellular Therapeuti...

1. A composition comprising a pharmaceutically acceptable carrier, an adjuvant, and a mixture of at least one major histocompatibility complex (MHC) class I peptide epitope of 8-10 amino acids in length derived from a mesothelin antigen variant having an amino acid sequence selected from the group consisting of: SEQ ID NOs: 19-25 and at least one MHC class I peptide epitope of 8-10 amino acids in length derived from each of at least six different antigens or variants thereof selected from the group consisting of:a mesothelin antigen, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NOs: 15-18;
an NY-ESO-1 antigen, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NO: 26 and SEQ ID NO: 27;
an FBP antigen, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NO: 28 and SEQ ID NO: 29;
a HER-2/neu antigen, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NOs: 30-48;
an IL-13 receptor ?2 antigen, wherein the MHC class I peptide epitope has an amino acid sequence of SEQ ID NO: 49;
a MAGE-A1 antigen, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NOs: 50-55;
an EphA2 antigen, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NOs: 56-68;
a p53 antigen or variant thereof, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NOs:69-80;
a k-Ras antigen or variant thereof, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NOs:81-86;
an Ep-CAM antigen, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NOs:87-91;
a MUC1 antigen or variant thereof, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NO:92 and SEQ ID NO:93;
a survivin antigen or variant thereof, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NOs:94-98;
an hTERT antigen or variant thereof, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NOs:99-104; and
a WT1 antigen, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NOs: 105-109.
US Pat. No. 10,137,438

HYDROPROCESSING CATALYST COMPOSITION AND PROCESS THEREOF

Indian Oil Corporation Li...

1. A catalyst precursor composition comprising:a. a first component comprising active sites, said first component being a surface modified clay and a pore modified zeolite, and
b. a second component being metal species comprising of at least one metal selected from Group VI B and at least one metal selected from VIII B;
wherein the second component is in intimate contact with the active sites of the first component;
wherein the surface modified clay is obtained by calcination at a temperature in the range of 500° C. to 1000° C., followed by controlled acid leaching of a kaolin clay and the pore modified zeolite is obtained by controlled acid leaching of a faujasite zeolite.
US Pat. No. 10,138,206

AMORPHOUS FORM OF LOMITAPIDE MESYLATE

GLENMARK PHARMACEUTICALS ...

1. A process for the preparation of an amorphous form of lomitapide mesylate free of alkyl mesylates comprising(a) providing a solution of lomitapide mesylate in a non-hydroxylic solvent; and
(b) isolating the amorphous form of lomitapide mesylate by
combining the solution obtained in (a) with an antisolvent followed by optional cooling to precipitate amorphous form of lomitapide mesylate, wherein the amorphous form of lomitapide mesylate has purity greater than 99.5% and a DSC endothermic peak at about 113±3° C. as shown in FIG. 2; wherein the non-hydroxylic solvent is ethyl acetate and the antisolvent is heptane.
US Pat. No. 10,138,463

SCALABLE PRIMATE PLURIPOTENT STEM CELL AGGREGATE SUSPENSION CULTURE AND DIFFERENTIATION THEREOF

VIACYTE, INC., San Diego...

1. A single chamber rolling bottle comprising primate pluripotent-derived cell aggregates in suspension in a physiologically acceptable medium, wherein the primate pluripotent-derived cell aggregates are derived from a single cell suspension of primate pluripotent stem cells agitated by rotation at a speed between about 3 to about 20 rpm.
US Pat. No. 10,138,719

METHOD OF EXTRACTING BITUMEN FROM OIL SANDS WITH A PROPYLENE OXIDE CAPPED GLYCOL

Dow Global Technologies L...

1. A bitumen recovery process comprising a step of treating oil sands with a propylene oxide capped glycol ether, wherein:the oil sands are recovered by surface mining and transported to a treatment area for the step of treating the oil sands with the propylene oxide capped glycol ether or the oil sands are recovered by in situ production and in situ treatment occurs during the step of treating the oil sands with the propylene oxide capped glycol ether, and
the propylene oxide capped glycol ether is described by the following structure:
RO—(C2H4O)n—CH2CH(CH3)OHwherein R is a linear, branched, cyclic alkyl, phenyl, or alkyl phenyl group and n is 1 to 10.
US Pat. No. 10,137,439

PROCESS AND CATALYST FOR THE PRODUCTION OF PYRIDINE AND ALKYL DERIVATIVES THEREOF

1. A method of enhancing the catalytic activity of zinc containing zeolite-based heterogeneous catalyst for the production of pyridine and its alkyl derivatives during a base synthesis reaction, the method comprising:(1) preparing an aqueous slurry comprising components (a) a zeolite selected the group consisting of ZSM-5, ZSM-11 and combinations thereof, (b) optionally zinc, (c) a binder and (d) clay in amounts sufficient to provide an L/B ratio of about 1.5 to about 4.0 in the final catalyst composition;
(2) spray drying the slurry to provide catalyst particles having a particle size of about 40 ?m to about 200 ?m;
(3) calcining the particles to provide a final catalyst composition having an L/B ratio of about 1.5 to about 4.0.
US Pat. No. 10,138,464

USE OF APOPTOTIC CELLS EX VIVO TO GENERATE REGULATORY T CELLS

Mallinckrodt Hospital Pro...

1. A method of generating T cells with regulatory activity (T regs), the method comprising incubating CD4+ leukocytes with autologous apoptotic peripheral blood mononuclear cells (ACs) and IL-10.
US Pat. No. 10,137,184

SCAFFOLDS FOR CELL TRANSPLANTATION

President and Fellows of ...

1. A cancer vaccine device comprising a scaffold composition comprising a polymer matrix and having open, interconnected macropores;a granulocyte-macrophage colony stimulating factor (GM-CSF) that recruits immune cells selected from macrophages, T-cells, B-cells, NK cells, and dendritic cells;
a tumor antigen; and
an immune response-promoting bioactive factor comprising a small molecule, wherein the GM-CSF, the tumor antigen, or the immune response-promoting bioactive factor is incorporated into or coated onto said scaffold composition.
US Pat. No. 10,138,465

DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS INTO PANCREATIC ENDOCRINE CELLS USING HB9 REGULATORS

Janssen Biotech, Inc., H...

1. A method for producing pancreatic endocrine cells from human pluripotent stem cells, comprising the steps of:(a) differentiating human pluripotent stem cells into foregut endoderm cells; and
(b) differentiating the foregut endoderm cells into pancreatic endocrine cells by treatment with a medium supplemented with (i) a thyroid hormone selected from triiodothyronine, thyroxine, analogues of triiodothyronine, analogues of thyroxine or mixtures thereof, or (ii) both thyroid hormone and an ALK5 inhibitor.
US Pat. No. 10,137,185

PAP PEPTIDE ANALOGUES

Nottingham Trent Universi...

1. A composition comprising a polypeptide of 9-42 amino acids, the polypeptide comprising at least amino acids 13-21 of SEQ ID No: 1 and said amino acids 13-21 of SEQ ID No: 1 has HLA-A2 haplotype binding activity.
US Pat. No. 10,137,441

METHOD FOR PRODUCING ALUMINOSILICATE CATALYST, ALUMINOSILICATE CATALYST, AND METHOD FOR PRODUCING MONOCYCLIC AROMATIC HYDROCARBONS

1. A method for producing an aluminosilicate catalyst, comprising:a first phosphorus treatment step of treating a crystalline aluminosilicate with a first phosphorus compound, wherein the crystalline aluminosilicate comprises at least one component selected from the group consisting of medium pore zeolites and large pore zeolites as a main component,
mixing a phosphorus-treated crystalline aluminosilicate obtained in the first phosphorus treatment step with a binder, molding a mixture of the phosphorus-treated crystalline aluminosilicate and the binder to form a molded body, and then firing the molded body, and
a second phosphorus treatment step of treating the fired molded body with a second phosphorus compound.
US Pat. No. 10,138,209

PROCESS FOR PURIFYING AN IONIC LIQUID

Evonik Degussa GmbH, Ess...

1. A process for purifying an ionic liquid of the structure Q+A?, wherein Q+ is a 1,3-dialkylimidazolium ion, and wherein A? is selected from the group consisting of: dialkyl phosphate; alkyl sulphate; alkyl sulphonate; alkyl carboxylate; chloride; hydrogen sulphate; dihydrogen phosphate; monoalkyl hydrogen phosphate; and nitrate;wherein the ionic liquid of the structure Q+A? is subjected to a stripping with water vapour having a temperature of ?99° C.
US Pat. No. 10,138,466

COMPOSITIONS AND METHODS FOR DIFFERENTIATING STEM CELLS INTO CELL POPULATIONS COMPRISING BETA-LIKE CELLS

REGENERATIVE MEDICAL SOLU...

1. A kit, comprising:differentiation medium comprising a B27 serum-free medium, IGF I, IGF II, FGF7, insulin, nicotinamide, exendin-4, ALK5i II, and forskolin.
US Pat. No. 10,138,467

MEDIUM FOR HIGH PERFORMANCE MAMMALIAN FED-BATCH CULTURES

ARES TRADING S.A., Aubon...

1. A cell culture medium comprising: 1.7 to 10 mM of NaH2PO4, 2 to 9 mM of L-Leucine, 1 to 6 mM of L-Lysine, 0 to 3 mM of Glycine, 0.4 to 2 mM of L-Methionine, 1 to 4 mM of L-Glutamic acid, 0.5 to 3 mM of L-phenylalanine, 0.7 to 6 mM of L-proline, 0.7 to 6 mM of L-threonine, 0.5 to 2 mM of L-tryptophan, 1 to 7 mM L-Valine, 0.1 to 1.5 mM of Magnesium Sulfate, 0.1 to 1.05 mM of Calcium Chloride, 0.07 to 0.7 mM of myo-Inositol, 0.8 to 4 mM of Sodium pyruvate, 0.0008 to 0.004 mM of D-Biotin, 0.1 to 1 mM of Choline Chloride, 3 to 9 mM of L-Asparagine, 0.006 to 0.04 mM of Folic acid, 0.03 to 0.15 mM of Niacinamide (B3), 0.015 to 0.15 mM of D-pantothenic acid×½Ca, 1 to 8 mM of L-Serine, 1 to 10 mM of Potassium Chloride, 0.005 to 0.05 mM of Pyridoxine, 0.8 to 2.4 mM of L-Aspartic acid, 0.0003 to 0.003 mM of Riboflavin, 0.008 to 0.04 mM of Thiamine, 7.5 to 10 mg/L of Ferric ammonium citrate, 0.0003 to 0.004 mM of Vitamin B12, 0.008 to 0.04 mM of Hypoxanthine, 0.0015 to 0.006 mM of Thymidine, 0.006 to 0.03 mM of Putrescine, 0.1 to 0.5 mM of Ethanolamine, 0.004 to 0.02 mM of Zinc Sulfate, 0.00004 to 0.0008 mM of Cupric sulfate, 0.5 to 2.0 g/L of poloxamer, 0.7 to 3 mM of L-tyrosine, 0.00001 to 0.00006 mM of Sodium Selenite, 0 to 3 mM of L-Alanine, 1 to 3 mM of L-Arginine, 1 to 3 mM of L-Cysteine, 0.4 to 3 mM of L-Histidine, and 1 to 6 mM of L-Isoleucine.
US Pat. No. 10,137,187

RECOMBINANT SUBUNIT DENGUE VIRUS VACCINE

1. A method for raising an immune response in a human patient, the method comprising administering a therapeutically effect amount of an immunogenic composition to the patient, wherein the immunogenic composition comprises an effective amount of purified dengue virus envelope (“E”) protein monomers of serotype DEN-1, DEN-2, DEN-3, and DEN-4, a pharmaceutically acceptable excipient, and an effective amount of adjuvant; wherein the E proteins each constitute approximately 80% of the length of wild type E starting from amino acid residue 1 at its N-terminus, such that said E protein is secretable into growth medium when expressed recombinantly in a host cell; wherein the amount of DEN4 E protein is about 1.5 to about 3 times the individual amounts of DEN1, DEN2, and DEN3 E proteins, and wherein the composition induces the production of neutralizing antibodies in human subjects.
US Pat. No. 10,138,211

CRYSTALLINE FORMS OF OLAPARIB AND MANUFACTURING PROCESSES THEREFOR

SCINOPHARM TAIWAN, LTD., ...

1. Crystalline form II of olaparib, characterized by an X-ray powder diffraction pattern comprising peaks at 6.8, 11.3, 14.4, 20.9, 21.7, and 25.0 degrees 2? (±0.2 degrees 2?); wherein the crystalline form II of olaparib is an anhydrous form.
US Pat. No. 10,138,468

METHOD FOR DIFFERENTIATION OF PLURIPOTENT STEM CELLS INTO MULTI-COMPETENT RENAL PRECURSORS

Hoffmann-La Roche Inc., ...

1. A method for differentiating human or mouse pluripotent stem cells into renal precursor cells expressing SIX2, WT1 and SALL1, the method comprising the steps of:a) providing a monolayer of human or mouse pluripotent stem cells in a pluripotency medium,
b) incubating the cells of step a) in an adherent culture for at least three days in a medium supplemented with 3-(3-amino-phenyl)-4-(1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione and recombinant bone morphogenic protein-4 (BMP4), and
c) differentiating the cells of step b) in a serum-free medium supplemented with recombinant bone morphogenic protein-7 (BMP7) and retinoic acid, to produce renal precursor cells expressing SIX2, WT1 and SALL1.
US Pat. No. 10,137,188

CELL LINES FOR VIRUS PRODUCTION AND METHODS OF USE

University of Georgia Res...

1. An engineered cell line, wherein cells of the engineered cell line comprise decreased endogenous expression of at least one coding region selected from Table I compared to a control cell line, wherein the at least one coding region is selected from ZNF205, CNTD2, SEC61G, ETS1, TAF1L, MCCD1, LY6G6C, BTN2A1, GLRXL, GCGR, or EP300, and wherein the cells comprise an edited genome that results in decreased endogenous expression of the coding region, wherein the edited genome comprises a mutation of the genomic DNA of the engineered cell compared to a control cell line.
US Pat. No. 10,138,469

SYNTHETIC PEPTIDE AND USE THEREOF

Toagosei Co., Ltd., Toky...

or a modified amino acid sequence formed by conservative substitution of one, two or three amino acid residues in the amino acid sequence and that induces reprogramming in at least one type of differentiated cell; andculturing the cell culture to which the peptide has been supplied and thereby inducing reprogramming of the target cell.
US Pat. No. 10,137,189

INFLUENZA VIRUS VACCINES AND USES THEREOF

Icahn School of Medicine ...

1. A method of immunizing a subject against an influenza virus comprising:(a) administering to the subject an effective amount of a first immunogenic composition comprising a first chimeric hemagglutinin (HA) polypeptide, wherein the first chimeric HA polypeptide comprises an influenza virus hemagglutinin stem domain and an influenza virus hemagglutinin globular head domain, wherein the influenza virus hemagglutinin globular head domain is heterologous to the influenza virus hemagglutinin stem domain; and
(b) subsequent to the administration of the first immunogenic composition to the subject, administering to the subject an effective amount of a second immunogenic composition comprising a second chimeric hemagglutinin (HA) polypeptide, wherein the second chimeric HA polypeptide comprises the stem domain of the HA from influenza virus A/California/4/2009 (H1N1) and the globular head domain of the HA from an influenza virus A/Vietnam/1203/2004 (H5), A/Indonesia/5/2005 (H5), A/Anhui/1/2005 (H5), A/Bar headed loose/Quinghai/1A/2005(H5), A/turkey/Turkey/1/2005 (H5), or A/whooperswan/Mongolia/244/2005 (H5),
and wherein the globular head domain of the first chimeric influenza virus HA polypeptide is different than the globular head domain of the second chimeric HA polypeptide.
US Pat. No. 10,138,470

MUTATED ENZYME HAVING DEHYDROGENASE ACTIVITY AND USE THEREOF

AMANO ENZYME INC., Nagoy...

1. A mutant enzyme consisting of an amino acid sequence that is 95% identical to SEQ ID NO: 1 and in which one or two or more of the amino acid(s) selected from the group consisting of the following (1) to (8) has/have been substituted by another amino acid in the amino acid sequence of a microorganism-derived cholesterol oxidase, the mutant enzyme having higher cholesterol dehydrogenase activity to cholesterol oxidase activity (CHDH activity/CHO activity) in comparison with the microorganism-derived cholesterol oxidase:(1) an amino acid corresponding to the amino acid at the position 113 of the amino acid sequence of SEQ ID NO: 1;
(2) an amino acid corresponding to the amino acid at the position 362 of the amino acid sequence of SEQ ID NO: 1;
(3) an amino acid corresponding to the amino acid at the position 402 of the amino acid sequence of SEQ ID NO: 1;
(4) an amino acid corresponding to the amino acid at the position 412 of the amino acid sequence of SEQ ID NO: 1;
(5) an amino acid corresponding to the amino acid at the position 468 of the amino acid sequence of SEQ ID NO: 1;
(6) an amino acid corresponding to the amino acid at the position 483 of the amino acid sequence of SEQ ID NO: 1;
(7) an amino acid corresponding to the amino acid at the position 518 of the amino acid sequence of SEQ ID NO: 1; and
(8) an amino acid corresponding to the amino acid at the position 519 of the amino acid sequence of SEQ ID NO: 1.
US Pat. No. 10,137,190

NUCLEIC ACID MOLECULES ENCODING FERRITIN-HEMAGGLUTININ FUSION PROTEINS

The United States of Amer...

1. A nucleic acid molecule comprising a nucleotide sequence encoding a fusion protein comprising a monomeric ferritin subunit protein joined to an influenza hemagglutinin protein, wherein the monomeric ferritin subunit comprises a domain that allows the fusion protein to self-assemble into nanoparticles.
US Pat. No. 10,138,471

INSERTION OF CHARGE IN THE HYDROPHOBIC INTERIOR OF PROTEINS AS A STRATEGY FOR ENGINEERING PH-SENSITIVE SWITCHES

THE JOHNS HOPKINS UNIVERS...

1. A non-naturally occurring protein comprising an artificial pH-sensitive conformational switch that responds to a change in pH, within a range of pH 5.0 to pH 9.0, by causing a cooperative unfolding transition of the protein, wherein the protein comprises two or more ionizable amino acid residues selected from Lys, Asp, and Glu, that titrate with a pKa value shifted relative to the normal pKa value in water for the one or more ionizable amino acid residues, and wherein the two or more ionizable amino acid residues comprise two or more alternative amino acid residues that have been substituted for two or more amino acid residues in an internal region of the protein.
US Pat. No. 10,137,191

METHODS AND COMPOSITIONS FOR INDUCING PROTECTIVE IMMUNITY AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION

Beth Israel Deaconess Med...

1. A vaccine combination for inducing an immune response against a human immunodeficiency virus (HIV) in a subject, comprising:(i) a primer composition comprising an immunogenically effective amount of one or more adenovirus 26 (rAd26) vectors encoding one or more HIV antigenic polypeptides comprising amino acid sequences selected from the group consisting of SEQ ID NOs: 1-4, and a pharmaceutically acceptable carrier;
(ii) a first booster composition comprising an immunogenically effective amount of an isolated HIV envelope polypeptide comprising at least one of a stabilized trimer of HIV gp140 comprising the amino acid sequence of SEQ ID NO: 5 and a stabilized trimer of HIV gp140 comprising the amino acid sequence of SEQ ID NO: 6, and a pharmaceutically acceptable carrier; and
(iii) a second booster composition comprising an immunogenically effective amount of one or more additional rAd26 vectors encoding one or more additional HIV antigenic polypeptides comprising amino acid sequences selected from the group consisting of SEQ ID NOs: 1-4, and a pharmaceutically acceptable carrier,
wherein the first booster composition is for administration together with the second booster composition to the subject after administration of the primer composition.
US Pat. No. 10,137,192

COMPOSITIONS OF VACCINES AND ADJUVANTS AND METHODS FOR THE TREATMENT OF URINARY TRACT INFECTIONS

Sequoia Sciences, Inc., ...

1. A vaccine composition comprising (i) an effective amount of FimCH or truncated FimH, and (ii) an effective amount of phosphorylated hexaacyl disaccharide or pharmaceutically acceptable salts thereof.
US Pat. No. 10,138,473

THERMOSTABLE PROTEASE VARIANTS

1. A polypeptide having protease activity comprising at least 95% identity to amino acids 1 to 177 of SEQ ID NO: 2 and a substitution at position 79 using SEQ ID NO: 2 for numbering, wherein the polypeptide has improved thermostability compared to the protease shown in amino acids 1 to 177 of SEQ ID NO: 2.
US Pat. No. 10,137,193

METHODS FOR TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-4R ANTAGONIST

Sanofi Biotechnology, (F...

1. A method for treating persistent asthma in a subject in need thereof comprising administering to the subject a combination therapy comprising:i) one or more maintenance doses of an inhaled corticosteroid (ICS),
ii) one or more maintenance doses of a long-acting beta2-adrenergic agonist (LABA),
iii) a loading dose of about 600 mg of an antibody or an antigen-binding fragment thereof that specifically binds to interleukin-4 receptor (IL-4R) comprising three Heavy chain Complementarity Determining Region (HCDR) sequences comprising SEQ ID NOs: 3, 4, and 5, and three Light chain Complementarity Determining Region (LCDR) sequences comprising SEQ ID NOs: 6, 7, and 8, and
iv) one or more maintenance doses of about 300 mg of the antibody or the antigen-binding fragment thereof,
wherein the ICS and LABA are administered for the duration of administration of the antibody or the antigen-binding fragment thereof.
US Pat. No. 10,137,449

FLUIDIC DEVICES, SYSTEMS, AND METHODS FOR ENCAPSULATING AND PARTITIONING REAGENTS, AND APPLICATIONS OF SAME

10X GENOMICS, INC., Plea...

1. A method for manufacturing a droplet generator, comprising:(a) injection molding a polymeric structure comprising:
(i) a first channel connected to a first end of a flow regulator, wherein said first channel is configured to receive a first fluid comprising a plurality of microcapsules;
(ii) a second channel connected to a droplet generation junction, wherein said second channel is configured to receive a second fluid that is immiscible with said first fluid;
(iii) a third channel connected to the droplet generation junction; and
(iv) a fourth channel connected to a second end of the flow regulator and to the droplet generation junction,
wherein a cross-section of said flow regulator (i) increases along a direction of flow from said first channel and decreases along a direction of flow to said fourth channel and (ii) is dimensioned to accept microcapsules of said plurality of microcapsules from said first channel and provide said microcapsules in said fourth channel;
wherein said fourth channel is configured to allow contact of a fluid comprising said microcapsules of said plurality of microcapsules with said second fluid from said second channel at said droplet generation junction to generate a droplet comprising a single microcapsule from said microcapsules of said plurality of microcapsules, and
wherein said third channel is configured to provide an outlet for said droplet from said droplet generation junction; and
(b) attaching a laminating structure to said polymeric structure, wherein said laminating structure seals said first channel, said second channel, said third channel, and said fourth channel.
US Pat. No. 10,138,474

SCAVENGER RECEPTOR UPTAKE FOR FABRY DISEASE ENZYME REPLACEMENT THERAPY

RESEARCH FOUNDATION OF TH...

1. A composition comprising a lysosomal enzyme directly conjugated to a negatively charged scavenger receptor ligand by way of a hydrolysable linker.
US Pat. No. 10,138,475

METHODS AND COMPOSITIONS FOR ISOLATING SMALL RNA MOLECULES

APPLIED BIOSYSTEMS, LLC, ...

1. A method for isolating RNA including small RNA molecules of from 10 to 100 nucleotides in length from cells comprising:a) lysing the cells with a lysing solution to produce a lysate wherein the lysing solution comprises guanidinium;
b) extracting the lysate with an extracting solution comprising a non-alcohol organic solvent to form an aqueous phase and an organic phase;
c) adding an alcohol solution to the aqueous phase to form a mixture of 50% to 60% alcohol;
d) applying the mixture to a solid support;
e) washing the solid support with a wash solution; and
f) eluting RNA including small RNA molecules from the solid support.
US Pat. No. 10,137,195

THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER

Ganymed Pharmaceuticals G...

1. A method of treating a cancer disease comprising administering to a human patient an antibody having the ability of binding to CLDN18.2, wherein the antibody is administered at a dose of at least 600 mg/m2 to 1200 mg/m2; andwherein the antibody mediates killing of cells expressing CLDN18.2 and
wherein the antibody is a chimeric antibody and comprises a heavy chain variable region (VH) having an amino acid sequence of SEQ ID NO: 32, and a light chain variable region (VL) having an amino acid sequence of SEQ ID NO: 39.
US Pat. No. 10,138,476

USING RNA-GUIDED FOKI NUCLEASES (RFNS) TO INCREASE SPECIFICITY FOR RNA-GUIDED GENOME EDITING

The General Hospital Corp...

1. A composition comprising:a nucleic acid encoding an RNA-guided FokI Nuclease (RFN) fusion protein comprising a FokI catalytic domain sequence fused to the amino terminus of a catalytically inactive Streptococcus pyogenes CRISPR-associated 9 (dCas9) protein comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 5, wherein said catalytically inactive S. pyogenes Cas9 has point mutations at amino acid residues corresponding to positions (i) D10, E762, H983, or D986, and (ii) H840 or N863 of S. pyogenes Cas9, an intervening linker from 2 to 30 amino acids; and
a nucleic acid encoding two guide RNAs that direct said RFN fusion protein to a first target genomic sequence and a second target genomic sequence, wherein the guide RNAs that direct said RFN fusion protein to said first target genomic sequence and said second target genomic sequence are spaced 10 to 20 nucleotides apart, and said first target genomic sequence comprises a PAM recognition sequence positioned upstream of said first target genomic sequence and said second target genomic sequence comprises a PAM recognition sequence positioned downstream of said second target genomic sequence.
US Pat. No. 10,137,196

DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY

Immunomedics, Inc., Morr...

1. A method of treating colorectal, lung, stomach, urinary bladder, renal, pancreatic, breast, ovarian, uterine, esophageal, urothelial or prostatic cancer comprising administering to a human patient with colorectal, lung, stomach, urinary bladder, renal, pancreatic, breast, ovarian, uterine, esophageal, urothelial or prostatic cancer an immunoconjugate comprising sacituzumab govitecan; wherein the immunoconjugate is administered at a dosage of between 6 mg/kg and 16 mg/kg, wherein the patient has failed to respond to at least one other therapy, prior to treatment with the immunoconjugate.
US Pat. No. 10,137,452

THERMAL UNIFORMITY FOR THERMAL CYCLER INSTRUMENTATION USING DYNAMIC CONTROL

LIFE TECHNOLOGIES CORPORA...

1. A method for performing polymerase chain reactions (PCR), the method comprising:measuring a first temperature, by a first sensor, of a first sample block sector of a sample block;
measuring a second temperature, by a second sensor, of a second sample block sector of the sample block, wherein the second sample block sector is located adjacent to the first sample block sector;
calculating, by a controller, a difference in temperature between the first temperature and the second temperature; and
adjusting, by the controller, the first temperature of the first sample block sector based on the difference in temperature to increase thermal uniformity across the first sample block sector and the second sample block sector during a PCR thermal protocol.
US Pat. No. 10,138,477

METHOD OF PRODUCING SECRETABLE ANTIBODIES BY EXPRESSION IN SACCHAROMYCES CEREVISIAE

MERCK PATENT GmbH, Darms...

1. A method for producing a selected population of antibodies, by expression, secretion, and presentation of a mixed population of antibodies on the surface of yeast cells, the method comprising the following steps:(a) providing host cells of the yeast species Saccharomyces cerevisiae that have been transfected with a first and a second nucleic acid molecule on expression plasmids, wherein the first nucleic acid molecule comprises a yeast GAL1 promoter and encodes a fusion protein, wherein the GAL1 promoter is capable of controlling the expression of said fusion protein as a function of cultivation conditions, and wherein said fusion protein comprises an alpha-agglutinin cell surface anchor protein and an Fc binding domain, and wherein the second nucleic acid molecule encodes an antibody of said mixed population of antibodies and is under the control of a permanently active promoter;
(b) cultivating said host cells of (a) in the presence of >10% w/v polyethylene glycol (PEG) having a molecular weight of >5,000 in the cultivation medium, under conditions whereby said mixed population of antibodies is simultaneously co-expressed in soluble form with said fusion protein, whereby said fusion protein is anchored to the surface of the host cell upon secretion, and whereby each host cell expresses an individual antibody of said mixed population of antibodies, and whereby said antibodies of said mixed population of antibodies are secreted from the host cells and bound in non-covalent form to said Fc binding domain of said fusion protein on the surface of each host cell,
(c) selecting and isolating a population of said host cells of (b) according to the affinity of individual antibodies in said mixed population of antibodies by binding a detection marker to said individual antibodies, wherein the detection marker is selective for said individual antibodies, and isolating the yeast cells which are bound to the detection marker,
(d) culturing said isolated host cells of (c) and expressing said individual antibodies selected in (c) under cultivation conditions wherein little or no expression of said fusion protein occurs and wherein the expressed antibodies from said second expression step are secreted from the yeast cell without binding to the surface of said isolated host cells of (c), and
(e) isolating the secreted antibodies expressed in (d) selected binding affinity.
US Pat. No. 10,137,197

PROCESS FOR PREPARING AN IMMUNOGLOBULIN PREPARATION

CSL Behring AG, Bern (CH...

1. A process for preparing an immunoglobulin preparation, wherein the process comprises adding proline to an initial immunoglobulin preparation comprising less than 15% (m/v) immunoglobulin, and concentrating the initial immunoglobulin preparation to prepare a final immunoglobulin preparation comprising at least 20% (m/v) immunoglobulin, and wherein proline is added to the initial immunoglobulin preparation such that the viscosity of the final immunoglobulin preparation is less than 17 mPa·s as measured by a falling ball viscosimeter at 20.0° C.
US Pat. No. 10,138,221

SALTS OF NILOTINIB AND POLYMORPHS THEREOF

Sun Pharmaceutical Indust...

1. An acid addition salt of nilotinib wherein the acid is 1,4-butanedisulfonic acid.